Biora Therapeutics, Inc. · OTC:BIORQ
Biora Therapeutics — Progenity — Q1 2021 Earnings Presentation
13 slides from Biora Therapeutics's earnings presentation, May 13, 2021
Slide 1: First Quarter 2021 Financial Results
First Quarter 2021 Financial Results May 13, 2021 Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains “forward-looking statements” within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical fa
Slide 3: Q1 2021 & Other Recent Corporate Highlights
Q1 2021 & Other Recent Corporate Highlights Continued to increase our INN position by 3.3M lives, reaching 149M total covered lives Announced pre-validation data for PREECLUDIATM test showing performance consistent with verification study Signed agreement with Ionis Pharmaceuticals to evaluate OBDS
Slide 4: R&D Pipeline Update
R&D Pipeline Update
Slide 5: Preeclampsia Rule-Out Test: Preecludia - Innovative Test to Address Unmet Need
Preeclampsia Rule-Out Test: PreecludiaTM Innovative Test to Address Unmet Need Henderson JT, et al. Preeclampsia Screening: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2017 Apr 25;317(16):1668-1683. Ananth CV, et al. Pre-eclampsia rates in the United States
Slide 6: GI Precision Medicine Programs: Drug/Device Combination Products and Drug Delivery
Initiated preclinical studies for PGN-OB1 and PGN-OB2 with first fully autonomous device in Q2 2021 Progress continues under current pharma partnerships Announced 1st clinical data supporting device auto-location and payload delivery in colon Announced positive pre-clinical safety/ PK & PD data for
Slide 7: GI Precision Medicine Programs: Ingestible GI Diagnostic Platforms
Expected to initiate clinical proof of concept study in Q2 2021 ACG Abstract Award/Oral Presentation: Clinical study demonstrating assay accuracy compared to invasive standard of care protocol Full function preclinical study planned for 2H 2021 Expected to initiate clinical proof of concept study in
Slide 8: First Quarter 2021 Financial Results
First Quarter 2021 Financial Results
Slide 9: Q1 Revenues Grow 72%
Q1 Revenues Grow 72% Q1 2021 revenues are up 72% vs. Q4 2020, consistent with prior guidance ASPs continuing to improve Maintaining 2021 core products revenue guidance range of $115-125M Revenue ($ millions) Illustrates $10.7M revenue reserve in Q4 2020
Slide 10: Expanding the In-Network Footprint
Expanding the In-Network Footprint In-Network Lives – Progenity (millions) + + 2019 Added 3.3 million regional plan covered lives in Q1 Expanding government and commercial payer coverage for average risk NIPT Continuing discussions for INN contracts with national and other regional plans +3.3M lives
Slide 11: Financial Overview
Financial Overview $ in millions ©2020 Progenity, Inc. All rights reserved. Includes $10.7M reserve for estimated future payor settlements Included $13.8M expense related to change in fair value of derivative liability Consists principally of $168.5M convertible notes debt 1 1 2 3 1 1 2
Slide 12: Near-Term Potential Catalysts
Near-Term Potential Catalysts Women’s Health GI & Pharmaceuticals PREECLUDIA Pre-Validation data Q2 2021 PREECLUDIA Validation data Q3 2021 Q4 2021 1H 2022 PREECLUDIA Targeted Launch WOMEN’S HEALTH In-network with additional key payors PREECLUDIA National Launch INNATAL 4 Verification & Validation G
Slide 13: Progenity
progenity’ (©2021 Progenity, ne. All rights reserved